D

Diffusion Pharmaceuticals Inc
NASDAQ:CRVO

Watchlist Manager
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Watchlist
Price: 8.23 USD -6.05% Market Closed
Market Cap: 67.9m USD
Have any thoughts about
Diffusion Pharmaceuticals Inc?
Write Note

Diffusion Pharmaceuticals Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Diffusion Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Cash from Financing Activities
$46.3m
CAGR 3-Years
12%
CAGR 5-Years
53%
CAGR 10-Years
4%
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Diffusion Pharmaceuticals Inc
Glance View

Market Cap
67.9m USD
Industry
Biotechnology

Diffusion Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2016-11-09. Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate, Trans Sodium Crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The firm is focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.

CRVO Intrinsic Value
9.55 USD
Undervaluation 14%
Intrinsic Value
Price
D

See Also

What is Diffusion Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
46.3m USD

Based on the financial report for Sep 30, 2024, Diffusion Pharmaceuticals Inc's Cash from Financing Activities amounts to 46.3m USD.

What is Diffusion Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
4%

Over the last year, the Cash from Financing Activities growth was 312%. The average annual Cash from Financing Activities growth rates for Diffusion Pharmaceuticals Inc have been 12% over the past three years , 53% over the past five years , and 4% over the past ten years .

Back to Top